The world’s first genetically modified stem cell trial for the treatment of cardiac disease has now treated more than three dozen of an expected 100 patients with “supercharged” cells to reverse damage after a heart attack.
The clinical trial, part of the ENACT-AMI (ENhanced Angiogenic Cell Therapy-Acute Myocardial Infarction) study, is led by Dr. Duncan Stewart, CEO and Scientific Director of the Ottawa Hospital Research Institute, and Dr. Michael Kutryk, a cardiologist at St. Michael’s Hospital in Toronto.
The world’s first gene therapy clinical trial for Fabry disease is set to launch. Supported by the Philip S. Orsino Facility for Cell Therapy at the University Health Network in Toronto, it will be led by Dr. Armand Keating in collaboration with physicians across Canada. Fabry disease is a rare condition caused by an inherited enzyme deficiency and can shorten lifespan by as much as 40 years.
To find out more about clinical trials and research projects currently underway in Canada, click here for information provided by CellCAN, Regenerative Medicine and Cell Therapy Network.